3D0A Stock Overview
A molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions primarily in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Telo Genomics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.035 |
| 52 Week High | CA$0.13 |
| 52 Week Low | CA$0.034 |
| Beta | 1.04 |
| 11 Month Change | -45.74% |
| 3 Month Change | -69.03% |
| 1 Year Change | -66.35% |
| 33 Year Change | -86.64% |
| 5 Year Change | -55.41% |
| Change since IPO | -98.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3D0A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -53.9% | -0.7% | -0.02% |
| 1Y | -66.3% | -17.2% | 8.2% |
Return vs Industry: 3D0A underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 3D0A underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 3D0A volatility | |
|---|---|
| 3D0A Average Weekly Movement | 65.5% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3D0A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3D0A's weekly volatility has increased from 46% to 66% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sabine Mai | www.telodx.com |
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions primarily in Canada. Its TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability to identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM that predicts newly diagnosed MM patients who may relapse on 1st line therapy; TeloMRD-D Enumaeration that identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD detected cells in post-transplant patients.
Telo Genomics Corp. Fundamentals Summary
| 3D0A fundamental statistics | |
|---|---|
| Market cap | €6.15m |
| Earnings (TTM) | -€1.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.0x
P/E RatioIs 3D0A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3D0A income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.71m |
| Earnings | -CA$2.71m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.036 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3D0A perform over the long term?
See historical performance and comparison